Trial Profile

An Open-Label Study of Aficamten for Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aficamten (Primary)
Indications Hypertrophic cardiomyopathy
Focus Adverse reactions; Registrational
Sponsors Corxel Pharmaceuticals

Most Recent Events

27 Oct 2024 According to a CORXEL media release, Ji Xing Pharmaceuticals name changed to CORXEL.
04 Mar 2024 Status changed from not yet recruiting to recruiting.
31 Oct 2023 Planned number of patients changed to 44.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com